Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.
Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results suggest that this risk might extend to subjects without any prior history of cardiovascular disease. We explore this potential ris...
Main Authors: | Nigam H Shah, Paea LePendu, Anna Bauer-Mehren, Yohannes T Ghebremariam, Srinivasan V Iyer, Jake Marcus, Kevin T Nead, John P Cooke, Nicholas J Leeper |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4462578?pdf=render |
Similar Items
-
Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes.
by: Nicholas J Leeper, et al.
Published: (2013-01-01) -
Automated detection of off-label drug use.
by: Kenneth Jung, et al.
Published: (2014-01-01) -
Usage of intravenous forms of proton pump inhibitors
by: Marijan Ivanuša
Published: (2006-12-01) -
Proton pump inhibitors usage and the risk of cancer
by: Hubert Wróblewski, et al.
Published: (2021-08-01) -
Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?
by: Yohannes T. Ghebre, et al.
Published: (2020-07-01)